Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting® 2018

VK2809 10 mg QOD

(n=13)

VK2809 10 mg QD

(n=11)

VK2809

combined

(n=24)

Placebo

(n=11)

Median relative % change in liver fat by MRI-PDFF

-56.5%

(p=0.0014)

-59.7%

(p=0.0003)

-58.1%

(p=0.0002)

-8.9%

Mean absolute % change in liver fat by MRI-PDFF

-8.9%

(p=0.011)

-10.6%

(p=0.0025)

-9.7%

(p=0.0019)

-0.9%

Percentage of patients experiencing ? 30% reduction in liver fat

76.9%

(p=0.012)

90.9%

(p=0.0019)

83.3%

(p=0.0011)

18.2%

Percentage of patients experiencing ? 50% reduction in liver fat

61.5%

(p=0.047)

72.7%

(p=0.03)

66.7%

(p=0.023)

18.2%